OncoCyte Corp Stock News

IRVINE, Calif., July 27, 2021 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics and monitoring company with the mission to improve patient outcomes by providing clear ins

After the end of the second quarter, let's take a look at where things stand in the InvestorPlace Best Stocks for 2021 contest. The post 10 Best Stocks for 2021: Where Do Things Stand Halfway Through

Oncology stocks like OncoCyte (OCX), PerkinElmer (PKI), Catalent (CTLT), Cardiff Oncology (CRDF) and NovoCure (NVCR) are expected to continue their run over the next few months.

RENO, Nev.--(BUSINESS WIRE)--Echelon Diagnostics and Oncocyte join forces to develop analytical software that can scale to support Oncocyte's clinical tests and solutions

OncoCyte Corporation (OCX) CEO Ronnie Andrews on Q1 2021 Results - Earnings Call Transcript

IRVINE, Calif., May 04, 2021 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points across the

DetermaIO now shown to predict immunotherapy response in four different tissue types suggesting potential pan-cancer applicability DetermaIO now shown to predict immunotherapy response in four differe

Oncocyte gains proprietary capabilities for immune therapy monitoring and transplant rejection testing, both from a standard blood sample

IRVINE, Calif., April 14, 2021 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points across t

Achieved primary endpoint demonstrating significant correlation between DetermaIO and two-year overall survival rate to atezolizumab in metastatic bladder cancer

IRVINE, Calif., April 06, 2021 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points across t

OncoCyte's pipeline of genomics-based cancer treatments bode well for its growth in the coming decade and OCX stock is already up 90% year-to-date. The post Best Stocks for 2021: OCX Got Off to a Fast

Enterprise Products Partners is an income powerhouse priced at 2011 levels. In a market favoring value stocks, EPD stock should enjoy 2021.

Oncocyte Corporation (OCX) CEO Ronnie Andrews on Q4 2020 Results - Earnings Call Transcript

OncoCyte (OCX) delivered earnings and revenue surprises of 10.00% and -52.10%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?